BIOMAT Database Logo BIOMAT Database Logo

Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. 1995

A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Bone Marrow Transplant Laboratory, URA CNRS 1456, University of Bordeaux II, France.

Thirty three patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in relapse after allogenic bone marrow transplantation (BMT) were treated with recombinant alpha-interferon (IFN). Ten patients received IFN for cytogenetic relapse (group I) and 23 (group II) for hematologic relapse. The starting dose of IFN varied from 1.7 to 6 million units/m2/day (median 3 x 10(6) U/m2/day). Among the 10 group I patients, 3 subsequently developed hematologic relapse. Of the other 7, a cytogenetic response was observed in 6 (complete 4, minor 2). Three of these responders are alive in complete cytogenetic remission. Of the 23 group II patients, 3 did not respond to IFN but 20 achieved a complete (CHR) (n = 14) or a partial hematologic response (PHR) (n = 6). Thirteen of the 14 CHR patients subsequently achieved a cytogenetic response (complete 7, minor 6). Seven of the latter 13 patients are still alive in complete cytogenetic remission (CCR). Thus, for the entire group of 33 patients, IFN was followed by CCR in 11 cases (33%); all these patients are still alive and the median follow-up in CCR is now 60.7 months (range 35.3-72.5 months). The BCR-ABL rearrangement was not detected by RT-PCR in 5 of the 10 patients analyzed. Eleven other patients developed either blast crisis or acceleration. The 3-year probability of survival from the start of IFN therapy probability of survival from the start of IFN therapy was 70 +/- 16% (95% CI) and was statistically higher for patients who achieved CCR than for the others.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D012086 Reoperation A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery. Revision, Joint,Revision, Surgical,Surgery, Repeat,Surgical Revision,Repeat Surgery,Revision Surgery,Joint Revision,Revision Surgeries,Surgery, Revision
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
November 2003, Bone marrow transplantation,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
February 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
June 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
May 1997, Bone marrow transplantation,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
October 1995, Bone marrow transplantation,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2011, British journal of haematology,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l'Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
November 2013, Bone marrow transplantation,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).
February 2000, British journal of haematology,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.
June 1995, Leukemia,
A Pigneux, and A Devergie, and M Pochitaloff, and B Rio, and E Archimbaud, and J Y Cahn, and V Leblond, and M Michallet, and J P Jouet, and F Guilhot
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
July 1996, Blood,
Copied contents to your clipboard!